Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back (Q57756393)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Amir Avan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Paola Pacetti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Michele Reni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Michele Milella

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Enrico Vasile

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Andrea Mambrini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Vanja Vaccaro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sara Caponi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Stefano Cereda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Godefridus J Peters

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Maurizio Cantore

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

4 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cancer

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1016-1022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

23 February 2020

cites work

1 reference

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

21 January 2018

1 reference

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

21 January 2018

1 reference

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).

21 January 2018

1 reference

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

21 January 2018

1 reference

Treatment trends in metastatic pancreatic cancer patients: Is it time to change?

21 January 2018

1 reference

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.

21 January 2018

1 reference

Psoriasis patients with basal cell carcinoma have more repair-mediated DNA strand-breaks after UVC damage in lymphocytes than psoriasis patients without basal cell carcinoma

21 January 2018

1 reference

Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes

21 January 2018

1 reference

Detection of DNA adducts using a quantitative long PCR technique and the fluorogenic 5' nuclease assay (TaqMan).

21 January 2018

1 reference

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

21 January 2018

1 reference

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

21 January 2018

1 reference

Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer

21 January 2018

1 reference

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

21 January 2018

1 reference

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

21 January 2018

1 reference

21 January 2018

1 reference

Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH

21 January 2018

1 reference

DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.

21 January 2018

1 reference

Basis for effective combination cancer chemotherapy with antimetabolites

21 January 2018

1 reference

DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28078

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23390054%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference